RMD250117C210000
- 24.86
- 0.000.00%
ResMed Newsroom
J.P. Morgan Remains a Buy on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Apple, AT&T, Tesla, GM, Microsoft, and More Stocks to Watch This Week
If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
We Like ResMed's (NYSE:RMD) Returns And Here's How They're Trending
Earnings Preview: ResMed to Report Financial Results Post-market on January 30
$ResMed(RMD.US)$ is scheduled to release its financial results post-market on January 30 ET. Earnings PreviewAnalysts estimate $ResMed(RMD.US)$ to post revenue of USD1.27B for 2025Q2, up 9.04% YOY;
Baird Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $286
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
ResMed Not Getting Enough Credit for Cost Control -- Market Talk
UBS Maintains ResMed(RMD.US) With Hold Rating, Raises Target Price to $255
Express News | Resmed Inc : UBS Raises Target Price to $255 From $250
Resmed Inc Elliott Wave Technical Forecast [Video]
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $270
Resmed Poised for Market Outperformance With Strong Growth Indicators and Strategic Advantages
Brokers Name 3 ASX Shares to Buy Today 17 January 2025
Citi Keeps Their Hold Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Download Growth Hints at Possible Sales Beat -- Market Talk
ResMed Initiated at Buy by Goldman Sachs
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
5 Sectors and Stocks Set to Shine This Earnings Season
Scoop Up These 4 GARP Stocks to Receive Handsome Returns